Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. (SLDB) files reports and disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed issuer. These SEC filings provide detailed information on the company’s clinical programs, financial condition, risk factors and material corporate events related to its development of precision genetic medicines for rare neuromuscular and cardiac diseases.
Among the documents available, Form 10-K annual reports and Form 10-Q quarterly reports typically discuss Solid Biosciences’ gene therapy pipeline, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia and SGT-601 for TNNT2-mediated dilated cardiomyopathy, along with its AAV-SLB101 capsid platform and broader development activities. These filings outline the company’s business description, research and development focus and key risks.
Form 8-K current reports, such as the filing describing interim data from the INSPIRE DUCHENNE Phase 1/2 trial of SGT-003, provide updates on material events, including clinical data readouts, regulatory developments, corporate presentations and other significant announcements. Investors can also review information on equity awards and stock plans, as referenced in company communications about inducement grants made under Nasdaq Listing Rule 5635(c)(4).
This SEC filings page offers real-time access to Solid Biosciences’ submissions from the EDGAR system, along with AI-powered summaries that highlight key points from lengthy documents. Users can quickly identify disclosures on clinical trial progress, gene therapy strategy, regulatory interactions and other factors that may be important when evaluating SLDB.
Solid Biosciences Inc. director Ilan Ganot reported equity transactions related to spouse-held awards and updated his share holdings. On January 3, 2026, 2,994 restricted stock units held by his wife converted into 2,994 shares of common stock, reflecting one-for-one conversion of these awards. On January 5, 2026, 1,053 shares of common stock associated with his wife were sold at $5.43 per share to cover withholding taxes after the vesting of previously granted restricted stock units, and the filing notes these sales do not represent a discretionary trade by Ms. Ganot.
Following these transactions, 17,278 shares of common stock are reported as indirectly owned through his wife. The filing also reports 95,413 shares of common stock held directly by Mr. Ganot (including shares held jointly with Annie Ganot) and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust, for which Adam and Annie Ganot serve as trustees.
Solid Biosciences (SLDB) director Ilan Ganot reported an open-market sale of common stock. On 11/10/2025, he sold 3,278 shares at a weighted average price of $4.12, executed in multiple trades within a $4.11–$4.12 range.
Following the transaction, he beneficially owned 95,412 shares directly. Additional indirect holdings reported include 14,839 shares held by his spouse and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences (SLDB) filed its Q3 2025 report, posting a net loss of $45.8 million, driven by higher R&D as clinical programs advanced. R&D was $38.9 million (vs. $27.3 million a year ago) and G&A was $9.2 million (vs. $7.9 million). Total operating expenses reached $48.1 million.
Liquidity remained strong with $236.1 million in cash, cash equivalents and available-for-sale securities as of September 30, 2025, and management indicates funding into the first half of 2027. The company strengthened its balance sheet earlier in the year via the February 2025 offering, yielding approximately $188.0 million in net proceeds and pre-funded warrants. Derivative liabilities tied to FA212 milestones were $6.6 million at quarter-end.
Pipeline updates included progress in SGT-003 (Duchenne), with interim data (as of September 29, 2025) described in the filing, ongoing screening for SGT-212 (FA), and IND/CTA clearances for SGT-501 (CPVT). Shares outstanding were 77,910,239 as of October 29, 2025.
Solid Biosciences (SLDB) filed an 8‑K announcing positive interim clinical data and a corporate update for SGT‑003, its gene therapy for Duchenne muscular dystrophy. The Phase 1/2 INSPIRE DUCHENNE trial has dosed 23 participants across 15 sites, with dosing expected to reach 30 by early 2026.
At Day 90 (N=10, ages 5–10), mean microdystrophin expression was 58% by western blot and mass spectrometry, and 51% microdystrophin‑positive fibers by immunofluorescence. Strong correlations linked microdystrophin to restoration of DAPC components, including beta‑sarcoglycan (0.95) and nNOS activity (0.95). Biomarkers of muscle injury improved, with mean reductions at Day 90 in CK, ALT, AST and LDH, and further improvements observed in limited Day 360 data. Early cardiac monitoring showed LVEF trending into normal ranges at Day 180 (N=8) and cTnI reductions.
Safety was generally favorable with steroids alone for prophylaxis; one treatment‑related Grade 3 immune‑mediated myositis resolved after steroid treatment, and dosing continued. The company plans to meet the FDA in the first half of 2026 to discuss potential registrational pathways and has initiated the Phase 3 IMPACT DUCHENNE study outside the U.S., with approvals in Canada and Australia.
Solid Biosciences (SLDB) Form 4: Chief Medical Officer Gabriel Brooks reported RSU vesting and a related tax sale. On 10/18/2025, 9,750 restricted stock units converted to common stock on a one-for-one basis. On 10/20/2025, 2,895 shares were sold at $5.96 to cover withholding taxes under a previously adopted durable automatic sale instruction letter, characterized as a sell-to-cover and not a discretionary trade.
Following these transactions, Brooks beneficially owned 33,819 common shares, held directly. The filing notes an additional 19,500 RSUs beneficially owned after the reported transactions. The RSU grant from 10/18/2023 vests over four years at 25% on each anniversary of the grant date.
Solid Biosciences Inc. director Ian F. Smith reported receipt of 4,573 restricted stock units that convert one-for-one into common shares. The filing shows the RSUs were granted on 01/06/2025 and, per the grant terms, vest in equal quarterly installments beginning three months after the grant with final vesting 12 months after the grant date. The report records the RSUs as acquired on 10/06/2025 and notes the units accelerate in full if the executive chair agreement terminates early or if there is a change in control. After the transaction the reporting person beneficially owns 126,692 shares of common stock. The filing was signed by an attorney-in-fact on 10/07/2025.
Form 4 filed for Ilan Ganot (director) reports option and restricted stock unit grants on 08/14/2025. The reporting person received an employee stock option to buy 37,500 shares at an exercise price of $6.17, exercisable through 08/14/2035. In addition, 18,750 restricted stock units (RSUs) were granted, each representing the contingent right to one share. Both holdings are reported as indirectly beneficially owned (I) via wife. The RSUs and option vest over four years, with 50% vesting on the second anniversary of the August 14, 2025 grant date and 25% each year thereafter. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Ganot on 08/18/2025.
Solid Biosciences Inc. reported that its Chief Operating Officer, David T. Howton, was granted equity awards on 08/14/2025 consisting of an employee stock option to buy 150,000 shares at an exercise price of $6.17 per share with an expiration date of 08/14/2035, and 75,000 restricted stock units (RSUs) that each convert into one share. After these grants, Mr. Howton beneficially owns 150,000 option shares and 75,000 RSUs, all held directly. The RSUs and the option vest over four years: 50% vests on the second anniversary of the grant and 25% vests on each of the third and fourth anniversaries.
Kevin Tan, CFO & Treasurer of Solid Biosciences Inc. (SLDB), received equity awards on August 14, 2025. The Form 4 shows a grant of 125,000 employee stock options with an exercise price of $6.17 and 62,500 restricted stock units (RSUs), each RSU representing a right to one share. The awards vest over four years: 50% of the original shares vest on the second anniversary of the grant and 25% vest annually thereafter until the fourth anniversary. Following the reported transaction, Mr. Tan beneficially owns 125,000 shares from the option and 62,500 shares from RSUs as direct ownership. The Form 4 was signed by Kimberly Cornwell as attorney-in-fact on 08/18/2025.
Paul Herzich, Chief Technology Officer of Solid Biosciences Inc. (SLDB), reported equity awards granted on 08/14/2025. The filing shows an employee stock option for 100,000 underlying shares with a stated exercise price of $6.17 and an associated record showing 100,000 shares of common stock underlying that option. The filing also reports 50,000 restricted stock units (RSUs), each representing a contingent right to one share, for 50,000 shares of common stock. The RSUs and the option were granted on the same date and the RSUs vest over four years: 50% on the second anniversary of the grant and 25% annually thereafter until the fourth anniversary. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Herzich on 08/18/2025.